Cargando…

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Joseph T., Leung, Kathy, Bushman, Mary, Kishore, Nishant, Niehus, Rene, de Salazar, Pablo M., Cowling, Benjamin J., Lipsitch, Marc, Leung, Gabriel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094929/
https://www.ncbi.nlm.nih.gov/pubmed/32284616
http://dx.doi.org/10.1038/s41591-020-0822-7
_version_ 1783510561031454720
author Wu, Joseph T.
Leung, Kathy
Bushman, Mary
Kishore, Nishant
Niehus, Rene
de Salazar, Pablo M.
Cowling, Benjamin J.
Lipsitch, Marc
Leung, Gabriel M.
author_facet Wu, Joseph T.
Leung, Kathy
Bushman, Mary
Kishore, Nishant
Niehus, Rene
de Salazar, Pablo M.
Cowling, Benjamin J.
Lipsitch, Marc
Leung, Gabriel M.
author_sort Wu, Joseph T.
collection PubMed
description As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death. Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9–2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169/48,557 = 4.5%) and the approximator(1) of deaths/deaths + recoveries (2,169/2,169 + 17,572 = 11%) as of 29 February 2020. Compared to those aged 30–59 years, those aged below 30 and above 59 years were 0.6 (0.3–1.1) and 5.1 (4.2–6.1) times more likely to die after developing symptoms. The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30–60 years).
format Online
Article
Text
id pubmed-7094929
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-70949292020-03-26 Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China Wu, Joseph T. Leung, Kathy Bushman, Mary Kishore, Nishant Niehus, Rene de Salazar, Pablo M. Cowling, Benjamin J. Lipsitch, Marc Leung, Gabriel M. Nat Med Letter As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death. Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9–2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169/48,557 = 4.5%) and the approximator(1) of deaths/deaths + recoveries (2,169/2,169 + 17,572 = 11%) as of 29 February 2020. Compared to those aged 30–59 years, those aged below 30 and above 59 years were 0.6 (0.3–1.1) and 5.1 (4.2–6.1) times more likely to die after developing symptoms. The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30–60 years). Nature Publishing Group US 2020-03-19 2020 /pmc/articles/PMC7094929/ /pubmed/32284616 http://dx.doi.org/10.1038/s41591-020-0822-7 Text en © The Author(s), under exclusive licence to Springer Nature America, Inc. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter
Wu, Joseph T.
Leung, Kathy
Bushman, Mary
Kishore, Nishant
Niehus, Rene
de Salazar, Pablo M.
Cowling, Benjamin J.
Lipsitch, Marc
Leung, Gabriel M.
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title_full Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title_fullStr Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title_full_unstemmed Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title_short Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
title_sort estimating clinical severity of covid-19 from the transmission dynamics in wuhan, china
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094929/
https://www.ncbi.nlm.nih.gov/pubmed/32284616
http://dx.doi.org/10.1038/s41591-020-0822-7
work_keys_str_mv AT wujosepht estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT leungkathy estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT bushmanmary estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT kishorenishant estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT niehusrene estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT desalazarpablom estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT cowlingbenjaminj estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT lipsitchmarc estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina
AT leunggabrielm estimatingclinicalseverityofcovid19fromthetransmissiondynamicsinwuhanchina